Cargando…
Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol
Medication adherence among patients with chronic diseases, such as COPD, may be suboptimal, and many factors contribute to this poor adherence. One major factor is the frequency of medication dosing. Once-daily dosing has been shown to be an important variable in medication adherence in chronic dise...
Autores principales: | Albertson, Timothy E, Harper, Richart, Murin, Susan, Sandrock, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321647/ https://www.ncbi.nlm.nih.gov/pubmed/25673975 http://dx.doi.org/10.2147/PPA.S71535 |
Ejemplares similares
-
Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD
por: Albertson, Timothy E, et al.
Publicado: (2019) -
Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol
por: Molino, Antonio, et al.
Publicado: (2018) -
New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol
por: Cazzola, Mario, et al.
Publicado: (2013) -
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
por: Day, Nicola C., et al.
Publicado: (2020) -
Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol
por: Singh, Dave, et al.
Publicado: (2016)